Compare Fresenius Kabi Onco. with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ALEMBIC PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ALEMBIC PHARMA FRESENIUS KABI ONCO./
ALEMBIC PHARMA
 
P/E (TTM) x 22.1 16.2 136.5% View Chart
P/BV x 3.1 3.7 83.5% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 FRESENIUS KABI ONCO.   ALEMBIC PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ALEMBIC PHARMA
Mar-19
FRESENIUS KABI ONCO./
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs176664 26.5%   
Low Rs79412 19.0%   
Sales per share (Unadj.) Rs37.7208.7 18.1%  
Earnings per share (Unadj.) Rs5.131.0 16.4%  
Cash flow per share (Unadj.) Rs6.737.1 18.1%  
Dividends per share (Unadj.) Rs05.50 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs42.5144.2 29.5%  
Shares outstanding (eoy) m158.23188.52 83.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.6 130.9%   
Avg P/E ratio x25.017.4 143.9%  
P/CF ratio (eoy) x18.914.5 130.5%  
Price / Book Value ratio x3.03.7 80.1%  
Dividend payout %017.7 0.0%   
Avg Mkt Cap Rs m20,135101,461 19.8%   
No. of employees `0001.2NA-   
Total wages/salary Rs m7037,467 9.4%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,96339,347 15.2%  
Other income Rs m1894 19.2%   
Total revenues Rs m5,98139,441 15.2%   
Gross profit Rs m1,4308,736 16.4%  
Depreciation Rs m2581,152 22.4%   
Interest Rs m-26184 -14.1%   
Profit before tax Rs m1,2167,493 16.2%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3421,568 21.8%   
Profit after tax Rs m8065,844 13.8%  
Gross profit margin %24.022.2 108.0%  
Effective tax rate %28.120.9 134.5%   
Net profit margin %13.514.9 91.0%  
BALANCE SHEET DATA
Current assets Rs m5,10219,577 26.1%   
Current liabilities Rs m2,38514,896 16.0%   
Net working cap to sales %45.611.9 382.9%  
Current ratio x2.11.3 162.7%  
Inventory Days Days15090 167.2%  
Debtors Days Days11345 249.8%  
Net fixed assets Rs m5,14827,097 19.0%   
Share capital Rs m158377 42.0%   
"Free" reserves Rs m6,55626,811 24.5%   
Net worth Rs m6,73227,188 24.8%   
Long term debt Rs m9524,993 19.1%   
Total assets Rs m10,38847,778 21.7%  
Interest coverage x-45.841.7 -109.8%   
Debt to equity ratio x0.10.2 77.0%  
Sales to assets ratio x0.60.8 69.7%   
Return on assets %7.512.6 59.5%  
Return on equity %12.021.5 55.7%  
Return on capital %14.623.6 61.9%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29819,453 27.2%   
Fx outflow Rs m1,7726,065 29.2%   
Net fx Rs m3,52513,388 26.3%   
CASH FLOW
From Operations Rs m1,2748,120 15.7%  
From Investments Rs m-1,204-7,556 15.9%  
From Financial Activity Rs m-196590 -33.2%  
Net Cashflow Rs m-1261,153 -11.0%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 2.9 10.3%  
FIIs % 9.6 9.1 105.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 13.9 65.5%  
Shareholders   42,599 49,328 86.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS